CYP2D6 and Endoxifen in Tamoxifen Therapy: A Tribute to David A. Flockhart

被引：1
|
作者：
Skaar, Todd C. [1 ]
Desta, Zeruesenay [1 ]
机构：
[1] Indiana Univ Sch Med, Dept Med, Div Clin Pharmacol, Indianapolis, IN 46202 USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2018年 / 103卷 / 05期
关键词：
BREAST-CANCER; METABOLITE; BIOTRANSFORMATION; GENOTYPE;
D O I：
10.1002/cpt.1039
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
This issue of Clinical Pharmacology & Therapeutics (CPT) includes the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for using CYP2D6 genotyping to guide tamoxifen therapy for breast cancer patients. CYP2D6 metabolizes tamoxifen to its more active metabolite, endoxifen, and patients with reduced CYP2D6 activity have reduced circulating endoxifen concentrations. In this associated commentary, we recognize and honor the late Dr. David Flockhart, who began the research and made early fundamental discoveries on tamoxifen that have now resulted in this guideline.
引用
收藏
页码：755 / 757
页数：3
相关论文
共 50 条
  • [41] CYP2D6 genotype and adverse effects as indicators of plasma endoxifen in breast cancer patients taking tamoxifen.
    Balakrishnar, Bavanthi
    Menzies, Alexander M.
    Ali, Sayed Sahanawaz
    Yeap, Shang Heng
    Gao, Bo
    Liddle, Chris
    Coulter, Sally
    Provan, Pamela
    Gebski, Val
    Hui, Rina
    Kefford, Richard
    Wilcken, Nicholas
    Balleine, Rosemary L.
    Gurney, Howard
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [42] The influences of adherence to tamoxifen and CYP2D6 pharmacogenetics on plasma concentrations of the active metabolite (Z)-endoxifen in breast cancer
    Casali da Rocha, Jose Claudio
    Nardin, Jeanine M.
    Schroth, Werner
    Almeida, Thais A.
    Muerdter, Thomas
    Picolotto, Solange
    Vendramini, Evelyn C. L.
    Hoppe, Reiner
    Kogin, Jenifer P.
    Miqueleto, Diandra
    Moraes, Silvia D. R.
    Schwab, Matthias
    Pecoits-Filho, Roberto F.
    Brauch, Hiltrud
    CANCER RESEARCH, 2020, 80 (04)
  • [43] The use of the 13C-dextromethorphan breath test for phenotyping CYP2D6 in breast cancer patients using tamoxifen: association with CYP2D6 genotype and serum endoxifen levels
    F. L. Opdam
    V. O. Dezentje
    J. den Hartigh
    A. S. Modak
    R. Vree
    E. Batman
    C. H. Smorenburg
    J. W. R. Nortier
    H. Gelderblom
    H.-J. Guchelaar
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 593 - 601
  • [44] The Influences of Adherence to Tamoxifen and CYP2D6 Pharmacogenetics on Plasma Concentrations of the Active Metabolite (Z)-Endoxifen in Breast Cancer
    Nardin, Jeanine Marie
    Schroth, Werner
    Almeida, Thais Abreu
    Muerdter, Thomas
    Picolotto, Solane
    Lima Vendramini, Evelyn Castillo
    Hoppe, Reiner
    Kogin, Jenifer Primon
    Miqueleto, Diandra
    Robaskievicz de Moraes, Silvia Dark
    Schwab, Matthias
    Pecoits-Filho, Roberto Flavio
    Brauch, Hiltrud
    Casali-da-Rocha, Jose Claudio
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2020, 13 (02): : 284 - 292
  • [45] The use of the 13C-dextromethorphan breath test for phenotyping CYP2D6 in breast cancer patients using tamoxifen: association with CYP2D6 genotype and serum endoxifen levels
    Opdam, F. L.
    Dezentje, V. O.
    den Hartigh, J.
    Modak, A. S.
    Vree, R.
    Batman, E.
    Smorenburg, C. H.
    Nortier, J. W. R.
    Gelderblom, H.
    Guchelaar, H. -J.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (03) : 593 - 601
  • [46] The effect of rs5758550 on CYP2D6☆2 phenotype and formation of endoxifen in breast cancer patients using tamoxifen
    Sanchez-Spitman, Anabel B.
    Moes, Dirk-Jan A. R.
    Gelderblom, Hans
    Dezentje, Vincent O.
    Swen, Jesse J.
    Guchelaar, Henk-Jan
    PHARMACOGENOMICS, 2017, 18 (12) : 1125 - 1132
  • [47] CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects
    Dezentje, V. O.
    Opdam, F. L.
    Gelderblom, H.
    den Hartigh, J.
    Van der Straaten, T.
    Vree, R.
    Maartense, E.
    Smorenburg, C. H.
    Putter, H.
    Dieudonne, A. S.
    Neven, P.
    Van de Velde, C. J. H.
    Nortier, J. W. R.
    Guchelaar, H. -J.
    BREAST CANCER RESEARCH AND TREATMENT, 2015, 153 (03) : 583 - 590
  • [48] A novel CYP2D6 scoring system for the prediction of CYP2D6 activity: Application to tamoxifen metabolism.
    Borges, S.
    Li, L.
    Robarge, J.
    Nguyen, A.
    Azzouz, F.
    Desta, Z.
    Skaar, T.
    Flockhart, D. A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 : S67 - S67
  • [49] CYP2D6 polymorphisms and endoxifen concentration in Chinese patients with breast cancer
    Xue, Cong
    Yang, Wei
    Hu, Anqi
    He, Caiyun
    Liao, Hai
    Chen, Meiting
    An, Xin
    Wang, Shusen
    Yuan, Zhongyu
    Xu, Fei
    Tang, Jun
    Li, Haifeng
    Li, Su
    Shao, Jianyong
    Shi, Yanxia
    BMC CANCER, 2025, 25 (01)
  • [50] Impact of CYP2D6 polymorphisms on endoxifen concentrations and breast cancer outcomes
    G S Hwang
    R Bhat
    R D Crutchley
    M V Trivedi
    The Pharmacogenomics Journal, 2018, 18 : 201 - 208
12345